# Poxel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/poxel

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.poxelpharma.com
- Total disclosed funding: $25M
- Latest round: Series A (Sep 9, 2014)
- Investors on record: 4

## About

Poxel SA is a biopharmaceutical company focused on developing innovative therapies for chronic diseases with metabolic components, specifically targeting conditions such as type 2 diabetes and non-alcoholic steatohepatitis (NASH).Founded in 2009, Poxel SA operates out of Lyon, France, focusing on the development of treatments for chronic metabolic diseases. The company has executed a total of 9 deals, with the latest funding round being a Private Placement/Follow on in November 2024, raising EUR 17.690 mn. The CEO is Thomas Kuhn, and the company was established under the leadership of founder Sophie Bozec.Poxel SA specializes in the development of innovative biopharmaceutical products targeting chronic diseases with metabolic components. The company's primary offerings include PXL065, a deuterium-stabilized R-pioglitazone designed for non-alcoholic steatohepatitis (NASH); PXL770, an adenosine monophosphate-activated protein kinase (AMPK) activator aimed at rare metabolic diseases; and TWYMEEG® (Imeglimin), approved in 2021 for the treatment of type 2 diabetes in Japan. Poxel's client base includes healthcare providers and pharmaceutical partners, with a significant collaboration with Sumitomo Pharma for the commercialization of Imeglimin in Japan, targeting regions with high metabolic disorder prevalence.In 2022, Poxel SA reported a revenue of EUR 710,260.5 and an EBITDA of EUR -22,482,799.4. The company generates revenue primarily through partnerships and sales of its pharmaceutical products, including royalties and sales-based payments from TWYMEEG®, marketed by Sumitomo Pharma in Japan.In November 2024, OrbiMed Advisors agreed to provide USD 50 million in non-dilutive financing to Poxel SA, which will support future royalties and sales-based payments from TWYMEEG® sales by Sumitomo Pharma in Japan. The company is focused on expanding its product line and entering new markets as its therapies progress through clinical trials, particularly in regions with significant unmet needs for metabolic disease treatments.

## Funding rounds

- Series A, Sep 9, 2014, $6.5M — Bpifrance Investissement
- Series A, Dec 18, 2012, $6.7M — Andera Partners, Bpifrance Investissement
- Series A, Jul 8, 2010, $12M — Andera Partners, Omnes Capital, Amundi

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Amundi (https://capitalatlas.ai/funds/amundi) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A